CA2824060C - Anti-tlr4 antibodies and methods of use thereof - Google Patents

Anti-tlr4 antibodies and methods of use thereof Download PDF

Info

Publication number
CA2824060C
CA2824060C CA2824060A CA2824060A CA2824060C CA 2824060 C CA2824060 C CA 2824060C CA 2824060 A CA2824060 A CA 2824060A CA 2824060 A CA2824060 A CA 2824060A CA 2824060 C CA2824060 C CA 2824060C
Authority
CA
Canada
Prior art keywords
antibody
seq
amino acid
antigen binding
tlr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2824060A
Other languages
English (en)
French (fr)
Other versions
CA2824060A1 (en
Inventor
Laurianne Santa Giovannoni
Marie Kosco-Vilbois
Katrien L. De Graaf
Domenico Bosco
Thierry Berney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novimmune SA
Original Assignee
Novimmune SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune SA filed Critical Novimmune SA
Publication of CA2824060A1 publication Critical patent/CA2824060A1/en
Application granted granted Critical
Publication of CA2824060C publication Critical patent/CA2824060C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2824060A 2011-01-10 2012-01-10 Anti-tlr4 antibodies and methods of use thereof Active CA2824060C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161431191P 2011-01-10 2011-01-10
US61/431,191 2011-01-10
PCT/US2012/020717 WO2012096917A1 (en) 2011-01-10 2012-01-10 Anti-tlr4 antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
CA2824060A1 CA2824060A1 (en) 2012-07-19
CA2824060C true CA2824060C (en) 2021-05-11

Family

ID=46455425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2824060A Active CA2824060C (en) 2011-01-10 2012-01-10 Anti-tlr4 antibodies and methods of use thereof

Country Status (7)

Country Link
US (4) US8734790B2 (cg-RX-API-DMAC7.html)
EP (2) EP2663330B1 (cg-RX-API-DMAC7.html)
JP (3) JP6289098B2 (cg-RX-API-DMAC7.html)
AU (2) AU2012205763B2 (cg-RX-API-DMAC7.html)
CA (1) CA2824060C (cg-RX-API-DMAC7.html)
ES (1) ES2721378T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012096917A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009012319A (es) * 2007-05-14 2010-03-01 Novimmune Sa Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.
EP2663330B1 (en) * 2011-01-10 2019-03-06 NovImmune S.A. Anti-tlr4 antibodies and methods of use thereof
US9453076B2 (en) * 2012-03-29 2016-09-27 Novimmune S.A. Anti-TLR4 antibodies and uses thereof
US9688769B2 (en) * 2013-10-22 2017-06-27 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
WO2015082716A1 (en) * 2013-12-06 2015-06-11 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
CA2994772A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
CN109481666B (zh) * 2018-12-21 2020-11-03 江苏省中医院 一种人体血液肿瘤pdx模型的建立方法
JP2023523096A (ja) * 2020-04-20 2023-06-01 エデサ バイオテック リサーチ インコーポレイテッド 急性呼吸促迫症候群を治療するための組成物および方法
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
JP4317817B2 (ja) * 2002-09-06 2009-08-19 アムジェン インコーポレイテッド 治療用ヒト抗ｉｌ−１ｒ１モノクローナル抗体
PT1711531E (pt) 2003-12-10 2012-04-18 Novimmune Sa Anticorpos neutralizantes anti tlr4/md-2 e métodos para a sua utilização
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US7674884B2 (en) 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
RU2401277C2 (ru) * 2004-01-07 2010-10-10 Чирон Корпорейшн Не мышиное анти-m-csf-антитело (варианты), его получение и использование
WO2007041218A2 (en) * 2005-09-30 2007-04-12 Oklahoma Medical Research Foundation Regulation of tool-like receptors on stem cells
MX2009012319A (es) 2007-05-14 2010-03-01 Novimmune Sa Polipeptidos que se unen a receptores fc con funciones efectoras modificadas.
WO2009013848A1 (ja) 2007-07-24 2009-01-29 Panasonic Corporation ニッケル水素電池用負極材料とその処理方法およびニッケル水素電池
WO2009138494A2 (en) 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
MX2011001911A (es) * 2008-08-18 2011-07-04 Pfizer Anticuerpos para ccr2.
EP2663330B1 (en) * 2011-01-10 2019-03-06 NovImmune S.A. Anti-tlr4 antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP3539987A1 (en) 2019-09-18
JP2017137319A (ja) 2017-08-10
EP2663330B1 (en) 2019-03-06
CA2824060A1 (en) 2012-07-19
JP6289098B2 (ja) 2018-03-07
US20200239566A1 (en) 2020-07-30
US20170267754A1 (en) 2017-09-21
AU2017201859A1 (en) 2017-04-06
US10421809B2 (en) 2019-09-24
EP2663330A4 (en) 2015-07-22
JP2014505056A (ja) 2014-02-27
WO2012096917A1 (en) 2012-07-19
ES2721378T3 (es) 2019-07-31
AU2017201859B2 (en) 2019-01-03
JP2019081796A (ja) 2019-05-30
AU2012205763B2 (en) 2016-12-22
US8734790B2 (en) 2014-05-27
US9512221B2 (en) 2016-12-06
EP2663330A1 (en) 2013-11-20
US20150010559A1 (en) 2015-01-08
US20120177648A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
CA2824060C (en) Anti-tlr4 antibodies and methods of use thereof
AU2012205763A1 (en) Anti-TLR4 antibodies and methods of use thereof
US10584172B2 (en) Humanized monoclonal antibodies and methods of use
CA2593561C (en) Combining therapies targeting multiple toll-like receptors and use thereof
AU2016315873A1 (en) Humanized anti-CD40 antibodies and uses thereof
RS63094B1 (sr) Varijante anti-cd40 antitela sa utišanim fc
JP2020019824A (ja) 抗ｔｌｒ４抗体およびその使用方法
AU2023362569A1 (en) Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
CA2971364C (en) Dicam-specific antibodies and uses thereof
AU2016201742B2 (en) Silent Fc variants of anti-CD40 antibodies
EA049172B1 (ru) АНТИТЕЛА К ИНТЕГРИНУ αvβ8 ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ПОЧЕК

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170104